Telix Pharmaceuticals (TLX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $10.69, +1.14% vs the prior close of $10.57.
- Volume 324.83K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
TLX rises 1.1% to $10.69. Closed at $10.69, +1.14% vs the prior close of $10.57. Day range $10.66–$10.94, opened at $10.92.
TLX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — TLX rises 1.1% to $10.69
- Closed at $10.69, +1.14% vs the prior close of $10.57. Day range $10.66–$10.94, opened at $10.92.
- Volume was 324.83K shares, 1.0x its 50-day average of 319.72K.
- Price is -7.2% vs its 50-day average ($11.52) and +9.1% vs its 200-day average ($9.80).
- 52-week range $6.28–$13.11; today's close sits at 65% of that range, 18.5% below the 52-week high.
Oct 15, 2026 — TLX dips 0.8% to $10.57, 3 down days in a row
- Closed at $10.57, -0.75% vs the prior close of $10.65. Day range $10.43–$10.59, opened at $10.52.
- Volume was 215.50K shares, 0.7x its 50-day average of 317.39K.
- Price is -8.2% vs its 50-day average ($11.52) and +8.0% vs its 200-day average ($9.78).
- 52-week range $6.28–$13.11; today's close sits at 63% of that range, 19.4% below the 52-week high.
- That makes 3 straight losses.
Oct 14, 2026 — TLX dips 2.5% to $10.65
- Closed at $10.65, -2.47% vs the prior close of $10.92. Day range $10.61–$10.77, opened at $10.71.
- Volume was 222.90K shares, 0.7x its 50-day average of 315.27K.
- Price is -7.5% vs its 50-day average ($11.51) and +9.0% vs its 200-day average ($9.77).
- 52-week range $6.28–$13.11; today's close sits at 64% of that range, 18.8% below the 52-week high.
Oct 13, 2026 — TLX slides 3.3% to $10.92
- Closed at $10.92, -3.28% vs the prior close of $11.29. Day range $10.86–$11.01, opened at $11.01.
- Volume was 350.80K shares, 1.1x its 50-day average of 310.69K.
- Price is -5.1% vs its 50-day average ($11.50) and +11.9% vs its 200-day average ($9.76).
- 52-week range $6.28–$13.11; today's close sits at 68% of that range, 16.7% below the 52-week high.
Oct 12, 2026 — TLX rises 0.7% to $11.29
- Closed at $11.29, +0.71% vs the prior close of $11.21. Day range $11.27–$11.39, opened at $11.30.
- Volume was 266.20K shares, 0.9x its 50-day average of 306.98K.
- Price is -1.7% vs its 50-day average ($11.49) and +15.9% vs its 200-day average ($9.74).
- 52-week range $6.28–$13.11; today's close sits at 73% of that range, 13.9% below the 52-week high.
Oct 9, 2026 — TLX rises 1.8% to $11.21
- Closed at $11.21, +1.82% vs the prior close of $11.01. Day range $11.08–$11.26, opened at $11.11.
- Volume was 313.00K shares, 1.0x its 50-day average of 302.09K.
- Price is -2.2% vs its 50-day average ($11.46) and +15.2% vs its 200-day average ($9.73).
- 52-week range $6.28–$13.11; today's close sits at 72% of that range, 14.5% below the 52-week high.
Oct 8, 2026 — TLX dips 1.0% to $11.01
- Closed at $11.01, -0.99% vs the prior close of $11.12. Day range $10.93–$11.10, opened at $11.08.
- Volume was 390.30K shares, 1.3x its 50-day average of 295.73K.
- Price is -3.7% vs its 50-day average ($11.44) and +13.4% vs its 200-day average ($9.71).
- 52-week range $6.28–$13.11; today's close sits at 69% of that range, 16.0% below the 52-week high.
Oct 7, 2026 — TLX jumps 3.2% to $11.12 on 2.9x normal volume
- Closed at $11.12, +3.15% vs the prior close of $10.78. Day range $11.00–$11.14, opened at $11.01.
- Volume was 817.40K shares, 2.9x its 50-day average of 280.72K — unusually heavy trading.
- Price is -2.6% vs its 50-day average ($11.42) and +14.7% vs its 200-day average ($9.70).
- 52-week range $6.28–$13.11; today's close sits at 71% of that range, 15.2% below the 52-week high.
Oct 6, 2026 — TLX dips 0.9% to $10.78
- Closed at $10.78, -0.92% vs the prior close of $10.88. Day range $10.73–$10.96, opened at $10.96.
- Volume was 230.70K shares, 0.8x its 50-day average of 278.24K.
- Price is -5.4% vs its 50-day average ($11.40) and +11.4% vs its 200-day average ($9.68).
- 52-week range $6.28–$13.11; today's close sits at 66% of that range, 17.8% below the 52-week high.
Oct 5, 2026 — TLX jumps 3.1% to $10.88
- Closed at $10.88, +3.13% vs the prior close of $10.55. Day range $10.79–$10.91, opened at $10.80.
- Volume was 235.30K shares, 0.9x its 50-day average of 275.19K.
- Price is -4.4% vs its 50-day average ($11.38) and +12.6% vs its 200-day average ($9.67).
- 52-week range $6.28–$13.11; today's close sits at 67% of that range, 17.0% below the 52-week high.
Oct 2, 2026 — TLX dips 1.6% to $10.55, a 1-month low, 4 down days in a row
- Closed at $10.55, -1.59% vs the prior close of $10.72. Day range $10.45–$10.64, opened at $10.64.
- Volume was 299.60K shares, 1.1x its 50-day average of 271.62K.
- Price is -7.2% vs its 50-day average ($11.37) and +9.3% vs its 200-day average ($9.65).
- 52-week range $6.28–$13.11; today's close sits at 63% of that range, 19.5% below the 52-week high.
- That makes 4 straight losses.
TLX latest news & SEC filings
Every SEC filing by or about TLX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 30, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 21, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Smith Darren Charlton bought 2,071 shares at $9.66 (≈$20.01K) on Sep 7, 2026
- Smith Darren Charlton bought 2,071 shares at $9.66 (≈$20.01K) on Sep 7, 2026
- Smith Darren Charlton bought 2,071 shares at $9.66 (≈$20.01K) on Sep 7, 2026
- Smith Darren Charlton bought 2,071 shares at $9.66 (≈$20.01K) on Sep 7, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 14, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 2, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 1, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 20, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 21, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jul 2, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Things to know before you trade TLX
- How much it moves: over the last 20 sessions the average daily move was 2.62% (largest 10.2%).
- Liquidity: about 433.31K shares (≈$4.63M) trade per day on average.
- 52-week position: $10.69 vs a range of $6.28–$13.11 (65% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 12 open-market buys, 0 sales; latest: Darren Charlton Smith bought 2,071 shares on Sep 7, 2026.
- Latest filings: 6-K Sep 30, 2026; 6-K Sep 21, 2026; 6-K Sep 14, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
TLX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 10.92 | 10.94 | 10.66 | 10.69 | 324.83K |
| Oct 15, 2026 | 10.52 | 10.59 | 10.43 | 10.57 | 215.50K |
| Oct 14, 2026 | 10.71 | 10.77 | 10.61 | 10.65 | 222.90K |
| Oct 13, 2026 | 11.01 | 11.01 | 10.86 | 10.92 | 350.80K |
| Oct 12, 2026 | 11.30 | 11.39 | 11.27 | 11.29 | 266.20K |
| Oct 9, 2026 | 11.11 | 11.26 | 11.08 | 11.21 | 313.00K |
| Oct 8, 2026 | 11.08 | 11.10 | 10.93 | 11.01 | 390.30K |
| Oct 7, 2026 | 11.01 | 11.14 | 11.00 | 11.12 | 817.40K |
| Oct 6, 2026 | 10.96 | 10.96 | 10.73 | 10.78 | 230.70K |
| Oct 5, 2026 | 10.80 | 10.91 | 10.79 | 10.88 | 235.30K |
| Oct 2, 2026 | 10.64 | 10.64 | 10.45 | 10.55 | 299.60K |
| Oct 1, 2026 | 10.90 | 10.94 | 10.72 | 10.72 | 201.70K |
| Sep 30, 2026 | 11.23 | 11.23 | 10.93 | 10.97 | 344.20K |
| Sep 29, 2026 | 11.64 | 11.64 | 11.23 | 11.34 | 427.60K |
| Sep 28, 2026 | 11.44 | 11.69 | 11.35 | 11.62 | 850.10K |
| Sep 25, 2026 | 11.30 | 11.45 | 11.27 | 11.45 | 408.30K |
| Sep 24, 2026 | 11.29 | 11.38 | 11.11 | 11.31 | 830.20K |
| Sep 23, 2026 | 11.41 | 11.45 | 11.20 | 11.27 | 462.70K |
| Sep 22, 2026 | 11.93 | 12.10 | 11.83 | 11.95 | 611.80K |
| Sep 21, 2026 | 11.24 | 11.60 | 10.76 | 11.31 | 863.10K |
About Telix Pharmaceuticals
Telix Pharmaceuticals (TLX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NORTH MELBOURNE, Australia. State of incorporation: Australia. Fiscal year ends December 31. SEC CIK 2007191.
TLX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Christian Behrenbruch | MD & Group CEO | May 6, 2026 |
| David N Gill | Director | May 18, 2026 |
| William R Jellison | Director | May 18, 2026 |
| Marie Elizabeth Mcdonald | Director | Mar 18, 2026 |
| Mark Alexander Nelson | Director | Apr 1, 2026 |
| Maria Rivas | Director | May 18, 2026 |
| Jann Elizabeth Skinner | Director | Mar 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Christian Behrenbruch | MD & Group CEO | May 6, 2026 |
| David Norman Cade | Group Chief Medical Officer | Apr 1, 2026 |
| Darren Joel Patti | Group Chief Operating Officer | Apr 1, 2026 |
| Darren Charlton Smith | Group Chief Financial Officer | Sep 14, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 7, 2026 | Darren Charlton Smith | Buy | 2,071 | $9.66 |
| Sep 7, 2026 | Darren Charlton Smith | Buy | 2,071 | $9.66 |
| Sep 7, 2026 | Darren Charlton Smith | Buy | 2,071 | $9.66 |
| Sep 7, 2026 | Darren Charlton Smith | Buy | 2,071 | $9.66 |
| Apr 29, 2026 | Christian Behrenbruch | Buy | 33,435 | $14.87 |
| Apr 29, 2026 | Christian Behrenbruch | Buy | 33,435 | $14.87 |
| Apr 29, 2026 | Christian Behrenbruch | Buy | 33,435 | $14.87 |
| Apr 29, 2026 | Christian Behrenbruch | Buy | 33,435 | $14.87 |
| Apr 28, 2026 | Christian Behrenbruch | Buy | 34,500 | $14.48 |
| Apr 28, 2026 | Christian Behrenbruch | Buy | 34,500 | $14.48 |
| Apr 28, 2026 | Christian Behrenbruch | Buy | 34,500 | $14.48 |
| Apr 28, 2026 | Christian Behrenbruch | Buy | 34,500 | $14.48 |
TLX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
TLX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on TLX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.